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Background
Cholera toxin and its two subunits (CTA,CTB) have
been intensively investigated as mucosal adjuvants for
protein based vaccine. In this study we evaluated the
adjuvanticity of CTA and CTB in modality of either
mixing their encoding plasmids with DNA vaccine or
fusing their encoding genes to immunogen encoding
gene.
Methods
DNA and recombinant vaccinia vaccines expressing HIV-1
AE strain tat, rev, intergrase(C-half), vif, nef fusion gene
(designated as TRIVN) have been constructed. For the
construction of fusion gene of CTA/CTB to TRIVN, over-
lapping PCR was employed to link CTA/CTB and TRIVN
gene, the fused genes(TRIVN-CTA and TRIVN-CTB)were
cloned into eukaryotic expression plasmid vector(pSV1.0).
Six groups of female BALB/c mice were immunized with
mock control, pSV-TRIVN, pSV-TRIVN-CTA, pSV-
TRIVN-CTB, pSV-TRIVN mixed with CTA or with CTB
respectively in a DNA priming-recombinant vaccinia
boosting regimen. Two weeks after the final injection,
mice splenocytes were collected and IFN-g ELISPOT assay
were used as readout for specific T cell response. Statisti-
cal analysis was performed by using Prism5.0 software.
Results
Our data showed that all constructed plasmids are capable
of efficiently expressing their inserted genes. All groups
immunized with vaccines raised significant more T-cell
response than mock control. T-cell responses elicited by
pSV-TRIVN-CTB(1548±330SFCs/106splenocytes) and
pSV-TRIVN-CTA (1642±514SFCs/106splenocytes)
were significantly higher than that by pSV1.0-TRIVN
(520±150SFCs/106splenocytes), pSV1.0-TRIVN mixed
with CTA (692±220SFCs/106splenocytes) and pSV1.0-
TRIVN mixed with CTB (734±240SFCs/106splenocytes).
Though TRIVN-CTA and TRIVN-CTB fusion vaccines
mounted comparable level of total IFN-g+ T-cell
responses, only TRIVN-CTB elicits significantly T-cell
responses against Tat, which is a subdominant component
in the fusion immunogen. No significant differences were
observed among groups inoculated with TRIVN alone or
adjuvanted by CTA/CTB subunit proteins.
Conclusion
CTA and CTB could serve as potent adjuvants for DNA
vaccine in immunogen-CTA/CTB fusion modality. Com-
pared with CTA, CTB may enhance T-cell responses
against subdominant epitopes in the immunogen and
broaden the T-cell immune responses.
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